These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 3157826)
81. [Principles of immunotherapy in insulin-dependent diabetes mellitus]. Bretzel RG Wien Klin Wochenschr; 1988 Jun; 100(13):435-42. PubMed ID: 3043913 [TBL] [Abstract][Full Text] [Related]
82. Dendritic cell mediated therapy for immunoregulation of type 1 diabetes mellitus. Phillips BE; Giannoukakis N; Trucco M Pediatr Endocrinol Rev; 2008 Jun; 5(4):873-9. PubMed ID: 18552749 [TBL] [Abstract][Full Text] [Related]
83. [Immunology of type-1 diabetes. The initial stages in a causal therapy]. Scherbaum WA; Hedderich U; Pfeiffer EF Dtsch Med Wochenschr; 1986 Apr; 111(15):593-6. PubMed ID: 3514198 [No Abstract] [Full Text] [Related]
84. [Will type I diabetes mellitus be treated with immunosuppressive drugs in the future?]. Diem P Ther Umsch; 1993 Feb; 50(2):114-8. PubMed ID: 8456415 [TBL] [Abstract][Full Text] [Related]
85. Immunological disorders of type 1 diabetes mellitus. Ziegler M; Ziegler B Exp Clin Endocrinol; 1989 Sep; 94(1-2):97-114. PubMed ID: 2689194 [TBL] [Abstract][Full Text] [Related]
86. On the pathogenesis of type 1 (insulin-dependent) diabetes mellitus: facts, areas still under development and new perspectives. Bottazzo GF; Bonifacio E; Wagner R; al-Sakkaf L; Dean BM; Mirakian R Klin Wochenschr; 1990; 68 Suppl 21():26-37. PubMed ID: 2198388 [TBL] [Abstract][Full Text] [Related]
87. Progress in the immunointervention of type-1 diabetes mellitus. Schernthaner G Horm Metab Res; 1995 Dec; 27(12):547-54. PubMed ID: 8750784 [TBL] [Abstract][Full Text] [Related]
88. Does partial preservation of residual beta-cell function justify immune intervention in recent onset Type I diabetes? Kolb H; Gale EA Diabetologia; 2001 Oct; 44(10):1349-53. PubMed ID: 11692186 [TBL] [Abstract][Full Text] [Related]
89. [Immunotherapy for type 1 diabetes mellitus (DM1)]. van der Torren CR; Roep BO Ned Tijdschr Geneeskd; 2012; 156(15):A4268. PubMed ID: 22495007 [TBL] [Abstract][Full Text] [Related]
90. Molecular biology of type 1 (insulin-dependent) diabetes mellitus. Lernmark A Diabetologia; 1985 Apr; 28(4):195-203. PubMed ID: 3160627 [No Abstract] [Full Text] [Related]
92. Remission Phase in Paediatric Type 1 Diabetes: New Understanding and Emerging Biomarkers. Fonolleda M; Murillo M; Vázquez F; Bel J; Vives-Pi M Horm Res Paediatr; 2017; 88(5):307-315. PubMed ID: 28772271 [TBL] [Abstract][Full Text] [Related]
93. Factors influencing remission phase in children with type 1 diabetes mellitus. Büyükgebiz A; Cemeroglu AP; Böber E; Mohn A; Chiarelli F J Pediatr Endocrinol Metab; 2001; 14(9):1585-96. PubMed ID: 11795651 [TBL] [Abstract][Full Text] [Related]
94. Immune intervention with T regulatory cells: past lessons and future perspectives for type 1 diabetes. Battaglia M; Roncarolo MG Semin Immunol; 2011 Jun; 23(3):182-94. PubMed ID: 21831659 [TBL] [Abstract][Full Text] [Related]
95. Interactions between islets and regulatory immune cells in health and type 1 diabetes. Budd MA; Monajemi M; Colpitts SJ; Crome SQ; Verchere CB; Levings MK Diabetologia; 2021 Nov; 64(11):2378-2388. PubMed ID: 34550422 [TBL] [Abstract][Full Text] [Related]
96. Impact of disease heterogeneity on treatment efficacy of immunotherapy in Type 1 diabetes: different shades of gray. Woittiez NJ; Roep BO Immunotherapy; 2015; 7(2):163-74. PubMed ID: 25713991 [TBL] [Abstract][Full Text] [Related]